Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | G6PD | P11413 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30199709 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1MAPTMEN1KMT2A | |
| SCHEMBL15541404 | 0.89 | PIN1 (0.52) | ALDH1A1MAPK1MAPTMEN1KMT2A | |
| SCHEMBL6320 | 0.87 | ALDH1A1 (0.55) | ALDH1A1MAPK1MAPTMEN1KMT2A | |
| SCHEMBL30585356 | 0.87 | ALDH1A1 (0.55) | ALDH1A1MAPK1MAPTMEN1KMT2A | |
| SCHEMBL9200645 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPK1MAPTMEN1KMT2A | |
| SCHEMBL1662886 | 0.84 | ALDH1A1 (0.65) | ALDH1A1MAPK1MAPTMEN1KMT2A | |
| SCHEMBL2986961 | 0.83 | MAPT (0.48) | ALDH1A1MAPK1MAPTMEN1KMT2A | |
| SCHEMBL1981547 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MAPK1MAPTMEN1KMT2A | |
| SCHEMBL2987569 | 0.83 | TLR4 (0.53) | MAPK1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL30639026 | 0.83 | MAPT (0.67) | ALDH1A1MAPK1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102199099-B | Method for preparing 3-bromo-4-methoxyaniline | UNIV CHANGZHOU | 2013-12-18 | — | — | CN | claimed |
| EP-4720036-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| US-12473264-B2 | Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4573088-A1 | HETEROCYCLE RBM39 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119630658-A | Heterocyclic RBM39 modulators | 递归医药公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-117945822-B | Reductive amidation method of triazine ester and nitroaromatic hydrocarbon | 南京工业大学 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024243692-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2024-12-05 | — | — | WO | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240228514-A1 | BORON-CONTAINING ORGANIC COMPOUND AND APPLICATIONS THEREOF | SHENZHEN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| CN-118221698-A | KRAS G12D inhibitors | 艾立康药业股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2007062996-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AND AZA-SUBSTITUTED INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050009830-A1 | Heterocyclic cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY. | 2005-01-13 | — | — | US | disclosed |
| US-6740650-B2 | SUCH AS 2,3-DIMETHOXY-DIBENZO(C,H)CINNOLINE FOR TREATMENT OF CANCER; FUNGICIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2004-05-25 | — | — | US | disclosed |
| US-20030100560-A1 | Heterocyclic cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2003-05-29 | — | — | US | disclosed |
| EP-1228045-A2 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032631-A2 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JEREY (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | IDO1, RB1, AHR | ALDH1A1 191/4885MAPK1 3379/4885MAPT 3825/4885 |
| US-20240228514-A1 | BORON-CONTAINING ORGANIC COMPOUND AND APPLICATIONS THEREOF | BCL6, SLCO4C1, SLCO2B1 | ALDH1A1 1928/4885MAPK1 1494/4885MAPT 1426/4885 |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | ALDH1A1 1598/4885MAPK1 2622/4885MAPT 1155/4885 |
| US-20050009830-A1 | Heterocyclic cytotoxic agents | CCNE1, RB1, CCNA1 | ALDH1A1 345/4885MAPK1 1784/4885MAPT 4872/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | ALDH1A1 2275/4885MAPK1 1633/4885MAPT 2593/4885 |
| US-20030100560-A1 | Heterocyclic cytotoxic agents | CCNA1, CCNE1, MCL1 | ALDH1A1 114/4885MAPK1 570/4885MAPT 4835/4885 |
| US-12473264-B2 | Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof | HBG1, SPTBN1, CTTN | ALDH1A1 2772/4885MAPK1 224/4885MAPT 2097/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | ALDH1A1 3257/4885MAPK1 221/4885MAPT 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.